OMecaMtiv Mecarbil
Price | USD1.00 |
Packge | 1ASSAYS |
- Min. Order:1ASSAYS
- Supply Ability:per week:100kg
- Time:2019-09-06
Product Details
- Product Name OMecaMtiv Mecarbil
- CAS No.873697-71-3
- EINECS No.850-774-6
- MFC20H24FN5O3
- MW401.43
- AppearanceSolidWhite to Off-White
- Melting point 180℃
- storage temp. -20°C Freezer
- Water Solubility 40.25mg/L at 25℃
Mary014
▼
▲
▼
▲
▼
▲
▼
▲
OMecaMtiv Mecarbil Basic information
▼
▲
Product Name:
Synonyms:
CK 1827452 - Omecamtiv Mecarbil | CK-452;OMecaMtiv Mecarbil;OMecaMtiv Mecarbil (CK-1827452);CK1827452;CK-1827452;CK-1827452 (OMecaMtiv Mecarbil);CK 1827452O;mecamtiv mecarbil
CAS:
MF:
C20H24FN5O3
MW:
401.4346632
EINECS:
Product Categories:
Mol File:
▼
▲
OMecaMtiv Mecarbil Chemical Properties
▼
▲
Melting point
180℃
▼
▲
Safety Information
▼
▲
▼
▲
OMecaMtiv Mecarbil Usage And Synthesis
▼
▲
Omecamtiv mecarbil (CK-1827452) is a specific cardiac myosin activator and a clinical drug for left ventricular systolic heart failure. Phase 2.
In vitro, Omecamtiv mecarbil selectively activates cardiac myosin by increasing the myosin ATPase rate. In isolated cardiac myocytes, Omecamtiv mecarbil results in increase of myocyte contractility and overcomes of the myosin inhibitor BDM without increasing the calcium transient or inhibiting the PDE pathway. [
Omecamtiv mecarbil significantly increases fractional shortening starting at 0.4 mM plasma concentrations in SD rats, sham animals and in rats with heart failure. In conscious dogs with myocardial infarction (MI-sHF), Omecamtiv mecarbil leads to a significant increase in wall thickening (25%), stroke volume (44%), cardiac output (22%) and left ventricular (LV) systolic ejection time (26%). In addition, Omecamtiv mecarbil also results in the decreases of some hemodynamic parameters including heart rate, mean left atrial pressure, and LV end-diastolic pressure. In conscious dogs with left ventricular hypertrophy (LVH-sHF), Omecamtiv mecarbil leads to similar and not statistically different effects on hemodynamic parameters.
Uses
CK 1827452 is a promising new drug in systolic heart failure. It accelerates the transition of myosin into the force-generating state without affecting cardiac myocyte calcium homeostasis. CK 1827452 increases cardiac function by increasing the duration of ejection without changing the rates of contraction.
▼
▲
OMecaMtiv Mecarbil Preparation Products And Raw materials
Company Profile Introduction
Henan CoreyChem Co., Ltd, based on the original Zhengzhou Cote Chemical Research Institute, be brave in absorbing highly educated talents & overseas returnees; actively responded to Zhengzhou City High-tech Zone Government’s Special Care Policy, reorganized and founded in National University of Science and Technology Park, which is a high-tech, stock enterprise of high-end chemical Custom synthesis;The park was created by the People's Government of Henan Province, and proved by Ministry of Education and the National Science & Technology, taking the construction mode of "many college a park, and common development", mainly depends on Zhengzhou University and Henan University’s scientific research and talent advantage to set up Universities, scientific research institute and enterprise scientific research achievements transformation platform, to make high-tech enterprises incubate, is the new high-tech talent gathering base, high and new technology industry enterprise radiation base, colleges and universities technological innovation base.
Henan Coreychem Co., Ltd, facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Corey have well-equipped machine, strong technical force and considerate marketing team service. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.
- Since:2014-12-17
- Address: No.967,15th Floor,Unit 7, Building 1, No.70 of DianChang Road, High-tech Development Zone, Zhengzho
INQUIRY